Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)

医学 肺癌 切除术 内科学 肿瘤科 前瞻性队列研究 化疗 放射治疗 外科
作者
NaiBin Chen,Qiwen Li,Siyu Wang,Mai Xiong,Yifeng Luo,Bin Wang,Li Chen,Maosheng Lin,Xiaobo Jiang,JianLan Fang,Suping Guo,JinYu Guo,Nan Hu,XinLei Ai,Daquan Wang,Chu Chu,FangJie Liu,Hao Long,Junye Wang,Bo Qiu
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:156: 82-90 被引量:5
标识
DOI:10.1016/j.lungcan.2021.04.020
摘要

ObjectivesTo explore the efficacy and toxicities of split-course hypo-fractionated radiotherapy with concurrent chemotherapy (HFRT−CHT) with intensity modulated radiotherapy (IMRT) technique in non-small cell lung cancer (NSCLC) patients with postoperative locoregional recurrence (LRR).Materials and MethodsNSCLC patients were eligible if confirmed as LRR disease without distant metastasis after complete resection. HFRT−CHT using IMRT technique was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break. Patients with no disease progression and no persistent Grade ≥2 toxicities had the second course of 15 Gy in 5 fractions or 28 Gy in 7 fractions as a boost. The primary endpoint was progression-free survival (PFS).ResultsFifty-eight patients were enrolled and analyzed. With a median follow-up of 23.9 months for all, the 2-year and 3-year PFS rate was 59.7 % and 46.4 %, the 2-year and 3-year OS rate was 72.5 % and 52.2 %, respectively, and a favorable objective response rate of 95.9 % was obtained after the whole courses protocol. Grade 3 acute pneumonitis and esophagitis occurred in 2 (3.4 %) and 7 (12.1 %) patients, and fatal pneumonitis was reported in one case (1.7 %). Exploratory subgroup analysis showed that performance status (PS) (PS 0 vs. 1: 2-year PFS, 88.1 % vs. 46.9 %,P = 0.001; 2-year OS, 100 % vs. 59.4 %, P < 0.001), recurrence site (single vs. multiple: 2-year PFS, 93.8 % vs. 47.4 %, P = 0.008; 2-year OS, 100 % vs. 63.0 %, P = 0.001), and gross tumor volume (GTV) (<50cm3 vs. ≥ 50cm3: 2-year PFS, 70.6 % vs. 46.2 %, P = 0.024; 2-year OS, 85.6 % vs. 57.4 %, P = 0.034) were significantly associated with PFS and OS.ConclusionSplit-course HFRT−CHT with IMRT technique achieved promising disease control and satisfactory survival with moderate toxicities in postoperative LRR of NSCLC. Good PS, a single recurrence site and GTV<50cm3 tended to have prolonged PFS and OS. Early detection of LRR may improve the efficacy of HFRT−CHT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
情怀应助付艳采纳,获得10
1秒前
3秒前
3秒前
独特的半芹完成签到,获得积分10
3秒前
粉面菜蛋完成签到,获得积分10
5秒前
5秒前
脑洞疼应助rrrrr采纳,获得10
7秒前
xiaojuan发布了新的文献求助10
9秒前
11秒前
12秒前
13秒前
14秒前
15秒前
jeff发布了新的文献求助10
16秒前
MchemG应助悲凉的妙松采纳,获得10
17秒前
18秒前
19秒前
小z发布了新的文献求助10
19秒前
xinghong完成签到,获得积分10
19秒前
白日焰火发布了新的文献求助10
20秒前
MenghuanXu发布了新的文献求助50
20秒前
20秒前
LLN发布了新的文献求助10
21秒前
紫曦完成签到,获得积分20
22秒前
852应助褚香旋采纳,获得10
23秒前
樊书雪发布了新的文献求助10
24秒前
紫曦发布了新的文献求助10
25秒前
奋斗的板栗完成签到,获得积分10
25秒前
枪王阿绣完成签到 ,获得积分10
26秒前
科目三应助威武的锅锅采纳,获得10
33秒前
阿星捌发布了新的文献求助10
34秒前
小z完成签到,获得积分10
34秒前
大个应助戴先森采纳,获得10
37秒前
39秒前
小手冰冰凉完成签到,获得积分10
39秒前
小笼包发布了新的文献求助10
40秒前
40秒前
浮云完成签到,获得积分10
41秒前
coolkid应助张安洋采纳,获得10
42秒前
贪玩的访风完成签到 ,获得积分10
42秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 1370
Secondary Ion Mass Spectrometry: Basic Concepts, Instrumental Aspects, Applications and Trends 1000
Comparison of adverse drug reactions of heparin and its derivates in the European Economic Area based on data from EudraVigilance between 2017 and 2021 500
[Relativity of the 5-year follow-up period as a criterion for cured cancer] 500
Statistical Analysis of fMRI Data, second edition (Mit Press) 2nd ed 500
Sellars and Davidson in Dialogue 500
Huang‘s catheter ablation of cardiac arrthymias 5th edtion 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3943024
求助须知:如何正确求助?哪些是违规求助? 3488034
关于积分的说明 11046786
捐赠科研通 3218664
什么是DOI,文献DOI怎么找? 1779086
邀请新用户注册赠送积分活动 864519
科研通“疑难数据库(出版商)”最低求助积分说明 799562